Neuroendocrine Tumor: Clinical Trials

40 trials for Neuroendocrine Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed, 5 recruiting, 4 terminated, 4 unknown. 14 Phase 2, 10 Not applicable, 6 Phase 1, 3 Early Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 214Completed 8, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1
Not applicable10Completed 7, Recruiting 2, Terminated 1
Phase 16Completed 3, Terminated 2, Unknown 1
Early Phase 13Recruiting 2, Completed 1
Phase 33Active not recruiting 2, Terminated 1

Follow Neuroendocrine Tumor: new trials by email Literature Review of Neuroendocrine Tumor trials Research Report on Neuroendocrine Tumor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
Computed Tomography, Gallium Ga 68-DOTA-FAPI-04, Positron Emission Tomography - Neuroendocrine Tumor
Early Phase 1RecruitingUniversity of Michigan Rogel Cancer Center302025-09-162026-07-31
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Biospecimen Collection, Exercise Intervention, Magnetic Resonance Imaging - Malignant Brain Neoplasm, Malignant Solid Neoplasm
Not applicableRecruitingMayo Clinic1472025-02-052026-06-10
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
PICO G2 4k - Cancer Pain, Visceral Pain
Not applicableRecruitingCedars-Sinai Medical Center3602021-10-052026-11-12
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection - Neuroendocrine Tumor, Liver Metastases
Phase 2RecruitingUniversity Hospital, Bordeaux232021-09-242025-07-23
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
18F-MFBG, 68Ga-Dotatate - Neuroendocrine Tumor, Neuroblastoma
Early Phase 1RecruitingPeking Union Medical College Hospital1502021-09-012024-03-01
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Lutetium-177 DOTATATE - Neuroendocrine Tumor
CompletedNovartis Pharmaceuticals312021-09-012023-04-18
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
oral protein supplements, placebo - Pancreatic Cancer, Cholangiocarcinoma
Not applicableCompletedYonsei University602021-01-072024-08-26
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Cabozantinib 40 mg - Neuroendocrine Tumor, Anaplastic Thyroid Cancer
Phase 2CompletedGrupo Espanol de Tumores Neuroendocrinos932020-10-072025-06-19
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Enterade®, Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0) - Neuroendocrine Tumor, Carcinoid Syndrome
Not applicableTerminatedVanderbilt-Ingram Cancer Center112019-11-042021-05-21
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Phase 3Active not recruitingNational Cancer Institute (NCI)2982018-10-262026-11-13
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
AlphaMedix - Neuroendocrine Tumor
Phase 1TerminatedOrano Med LLC332018-02-052025-06-10
A Study of XmAb®18087 in Subjects With NET and GIST
XmAb18087 - Neuroendocrine Tumor, Gastrointestinal Neoplasm
Phase 1CompletedXencor, Inc.622018-01-222022-05-10
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
90Y-DOTA-TOC, 68Ga-DOTA-TOC - Neuroendocrine Tumor
Early Phase 1CompletedThomas Hope102017-07-012020-07-07
Surgical Intervention and the NETest
Surgery - Neuroendocrine Tumor, Gastroenteropancreatic
Not applicableCompletedWren Laboratories LLC302017-05-152026-08-21
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
Vitamin supplement;, Diet advice - Neuroendocrine Tumor
Not applicableCompletedUniversity Medical Center Groningen532016-12-152024-05-06
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
pembrolizumab - Advanced Cancer, Anal Carcinoma
Phase 2Active not recruitingMerck Sharp & Dohme LLC16092015-12-182025-09-22
Optimal Feeding for NET Patients
Dietary intervention, Standard treatment - Neuroendocrine Tumor
Not applicableCompletedUniversity Medical Center Groningen152015-05-012024-05-06
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor
Web-based tailored information and support system, Standard care - Neuroendocrine Tumor
Not applicableCompletedUniversity Medical Center Groningen912015-05-012024-05-06
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
NETest - Neuroendocrine Tumor, Carcinoid
Enrolling by invitationWren Laboratories LLC4002015-02-012025-11-13
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma
Phase 1 / Phase 2TerminatedUniversity of California, San Francisco3002014-06-232019-11-12

Showing 20 of 40. Sign in to see all of them.

Narrower conditions

Neuroendocrine Tumors (40)  ·  Carcinoid Tumor (9)  ·  Adenoma, Islet Cell (7)  ·  Neoplasms (4)  ·  Neuroblastoma (4)  ·  Carcinoma, Islet Cell (3)  ·  Carcinoma, Neuroendocrine (3)  ·  Pancreatic Neoplasms (3)  ·  Paraganglioma (3)  ·  Somatostatinoma (3)  ·  Anus Neoplasms (2)  ·  Bile Duct Neoplasms (2)  ·  Biliary Tract Neoplasms (2)  ·  Cholangiocarcinoma (2)  ·  Gastrinoma (2)

Broader conditions

Neoplasms by Histologic Type (40)  ·  Neoplasms, Germ Cell and Embryonal (40)  ·  Neoplasms, Nerve Tissue (40)  ·  Neuroectodermal Tumors (40)  ·  Neoplasms (36)  ·  Neoplasms, Glandular and Epithelial (18)  ·  Neoplasms by Site (15)  ·  Adenocarcinoma (14)  ·  Carcinoma (14)  ·  Digestive System Diseases (14)  ·  Digestive System Neoplasms (14)  ·  Endocrine Gland Neoplasms (13)  ·  Endocrine System Diseases (13)  ·  Pancreatic Diseases (12)  ·  Adenoma (9)

Interventions

Magnetic Resonance Spectroscopy (6)  ·  gallium Ga 68 dotatate (4)  ·  Everolimus (3)  ·  Bevacizumab (2)  ·  Sorafenib (2)  ·  Specimen Handling (2)  ·  cabozantinib (2)  ·  3-fluorobenzylguanidine (1)  ·  68Ga-FAPI (1)  ·  90Y-octreotide, DOTA-Tyr(3)- (1)  ·  Acetates (1)  ·  Diet Therapy (1)  ·  Disulfides (1)  ·  Fluorouracil (1)  ·  Ga(III)-DOTATOC (1)

Sponsors

University Medical Center Groningen (5)  ·  Dana-Farber Cancer Institute (4)  ·  National Cancer Institute (NCI) (3)  ·  Novartis Pharmaceuticals (2)  ·  University of California, San Francisco (2)  ·  Wren Laboratories LLC (2)  ·  Cedars-Sinai Medical Center (1)  ·  Fox Chase Cancer Center (1)  ·  Grupo Espanol de Tumores Neuroendocrinos (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Hadassah Medical Organization (1)  ·  Mayo Clinic (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Nuclear Medicine Consultants, Inc. (1)  ·  Ochsner Health System (1)

Countries

United States (26)  ·  Netherlands (6)  ·  France (2)  ·  Italy (2)  ·  South Korea (2)  ·  Spain (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  Denmark (1)  ·  Germany (1)  ·  Israel (1)  ·  Sweden (1)

Top investigators

A. M.E. Walenkamp, MD, PhD (2)  ·  Annemiek ME Walenkamp, MD, PhD (1)  ·  Benjamin Viglianti (1)  ·  Brennan Spiegel, MD, MSHS (1)  ·  Emily K. Bergsland, MD (1)  ·  Emily R. Winslow, MD (1)  ·  Fang Li (1)  ·  James C Yao (1)  ·  Jaume Capdevila, M.D, Ph.D (1)  ·  Jennifer A Chan (1)  ·  Jennifer Ang Chan, MD, MPH (1)

Results publications

PMID 22736724, PMID 23475104, PMID 23989950, PMID 26032155, PMID 26370353, PMID 26456125, PMID 28185086, PMID 28384065, PMID 30158287, PMID 30819238, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32392558, PMID 32919526, PMID 33152282, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36748723, PMID 37160439, PMID 39282913, PMID 39945192, PMID 39979665, PMID 40121391, PMID 40717185, PMID 41524552, PMID 41920388

NIH funding

2015 (1), 2019 (1), N01CM62205 (1), P30CA006927 (1), P30CA086862 (1), R01CA167632 (1), R01CA252211 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1)